Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
Go back to Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting| (NASDAQ: RZLT) | Delayed: 4.00 +0.14 (3.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.86 | 52 Week High | $ | |||
| Open | $3.86 | 52 Week Low | $ | |||
| Day High | $4.23 | P/E | N/A | |||
| Day Low | $3.86 | EPS | $ | |||
| Volume | 1,312,012 | |||||
